| |OCTOBER 20249FDA APPROVES EXACT SCIENCE'S COLOGUARD PLUS TEST AFTER BLUE-C STUDYASTRAZENECA SIGNS BILLION DOLLAR DEAL WITH CHINA'S CSPC PHARMAINDIA PHARMA OUTLOExact Sciences Corp., a top supplier of cancer screening and diagnostic exams, disclosed that the Cologuard Plus test, the firm's advanced multitarget stool DNA test, was given the approval by the US Food and Drug Administration (FDA). The Cologuard Plus test is now authorized for individuals aged 45 and above with medium risk for colorectal cancer (CRC). FDA approval was granted after results from the significant BLUE-C study, one of the most extensive direct comparison studies in CRC screening, were examined.Within a group of almost 19,000 average-risk individuals, the Cologuard Plus test showed 95 percent sensitivity for all cancers and 43 percent sensitivity for advanced precancerous lesions at 94 percent specificity, with no abnormalities detected during colonoscopy. Findings from BLUE-C also indicate that the Cologuard Plus test performed much better than an independent fecal immunochemical test (FIT) in terms of overall sensitivity for colorectal cancer, sensitivity for treatable-stage colorectal cancer (stages I-III), sensitivity for high-grade dysplasia, and sensitivity for advanced precancerous lesions.The company specializing in molecular diagnostics is a top supplier of cancer screening and diagnostic exams that offer patients and healthcare providers the necessary understanding to make impactful decisions sooner. Following the achievements of the Cologuard and Oncotype tests, Exact Sciences is expanding its investments in developing innovative solutions for use in all stages of cancer diagnosis. POAstraZeneca, a British company, has partnered exclusively with CSPC Pharmaceutical Group from China to further develop a new small molecule disruptor for Lipoprotein (a) (Lp(a)), which could provide extra benefits for dyslipidemia patients. This asset enhances the company's cardiovascular portfolio to target the main risk factors of chronic cardiovascular disease.As per the agreement, AstraZeneca will obtain rights to CSPC's pre-clinical compound YS2302018, an oral Lp(a) disruptor, to develop it into a new lipid-lowering treatment for various cardiovascular diseases, either alone or in combination with the oral small molecule PCSK9 inhibitor, AZD0780.CSPC discovered YS2302018, which has been proven to effectively block the creation of Lp(a). Lp(a) is a type of LDL that has an important function in moving cholesterol through the bloodstream. Increased levels of Lp(a) and high LDL-cholesterol are recognized as risk factors for cardiovascular diseases such as coronary artery disease and stroke.The pharmaceutical firm will make an initial payment of $100 million to CSPC. CSPC can also potentially receive up to $1.92 billion for additional development and commercialization achievements as well as tiered royalties. PO
< Page 8 | Page 10 >